Primary Clarithromycin Resistance to <i>Helicobacter pylori</i> and Therapy Failure in Children: The Experience in West Virginia

Elitsur, Yoram; Lawrence, Zandra; Rüssmann, Holger; Koletzko, Sibylle

doi:10.1097/01.mpg.0000214157.52822.40

Cited by 16 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of few surveys conducted, currently, the rates of clarithromycin resistance in Africa and Oceania were reported to be at relatively low level. Unexpectedly, although the reported data of antibiotic resistance of H. pylori were limited, the prevalence of clarithromycin‐resistant H. pylori were high in America , the developed country.…”

Section: Prevalence Of Clarithromycin‐resistant Helicobacter Pylori Imentioning

confidence: 99%

Detection of Clarithromycin‐Resistant Helicobacter pylori by Stool PCR in Children: A Comprehensive Review of Literature

Xiong

Wang

et al. 2012

Helicobacter

View full text Add to dashboard Cite

show abstract

Section: Prevalence Of Clarithromycin‐resistant Helicobacter Pylori Imentioning

confidence: 99%

Detection of Clarithromycin‐Resistant Helicobacter pylori by Stool PCR in Children: A Comprehensive Review of Literature

Xiong

Wang

et al. 2012

Helicobacter

View full text Add to dashboard Cite

show abstract

“…In Central Europe, the recommended first line eradication treatment of H. pylori comprises clarithromycin, amoxicillin and a proton pump inhibitor [7,8]. Particularly with regard to clarithromycin resistance, treatment failure is highly likely if a clarithromycin‐containing regime is used [9–11]. During EGD, biopsy sampling for H. pylori culture and antimicrobial susceptibility determination is recommended especially in regions where resistances to antibiotics used as a part of the standard treatment are prevalent [12,13].…”

mentioning

confidence: 99%

Time Trends of Helicobacter pylori Resistance to Antibiotics in Children Living in Vienna, Austria

et al. 2010

View full text Add to dashboard Cite

show abstract

“…However, resistance to clarithromycin has become one of the major reasons for treatment failure (13). The prevalence of H. pylori resistance to clarithromycin varies among different countries, such as 10.6% to 25% in North America, 16% in Japan, and 1.7% to 23.4% in Europe (14,19,21). Overall, resistance to clarithromycin has been detected more in patients living in the south than in those living in the north of Europe (21).…”

mentioning

confidence: 99%

High Prevalence of Clarithromycin-Resistant Helicobacter pylori Strains and Risk Factors Associated with Resistance in Madrid, Spain

et al. 2010

View full text Add to dashboard Cite

Clarithromycin is one of the antibiotics used for the treatment of Helicobacter pylori infections, and clarithromycin resistance is the most important factor when it comes to predicting eradication failure. The present study analyzed H. pylori isolates for the presence of 23S rRNA gene mutations and determined the risk factors associated with resistance among H. pylori isolates collected in Madrid, Spain, in 2008. We studied 118 H. pylori strains isolated from the same number of patients. A total of 76.3% of the patients were born in Spain, 52.7% were children, 20.3% had previously been treated, and 66.1% were female. Clarithromycin resistance was determined by Etest. H. pylori strains were considered resistant if the MIC was >1 mg/liter. DNA extraction was carried out by use of the NucliSens easyMAG platform with NucliSens magnetic extraction reagents (bioMérieux). The DNA sequences of the 23S rRNA genes of clarithromycin-resistant and -sensitive strains were determined to identify specific point mutations. The vacA genotype and cagA status were determined by PCR. We found that 42 (35.6%) strains were resistant to clarithromycin by Etest. Etest results were confirmed by detection of the presence of point mutations in 34 (88.1%) of these strains. Eight H. pylori strains were resistant to clarithromycin by Etest but did not have a point mutation in the 23S rRNA gene. Mutation at A2143G was found in 85.3% of the strains, mutation at A2142G in 8.8%, and mutation at T2182C in 5.9%. Dual mutations were found in 8.8% of the strains. H. pylori clarithromycin-resistant strains were strongly associated with pediatric patients, with patients born in Spain, and with patients who had previously been treated (P < 0.02). In addition, H. pylori strains resistant to clarithromycin more frequently presented the vacA s2/m2 genotype and were more likely to be cagA negative than susceptible strains (39.1% and 11.2%, respectively; P value < 0.001). We concluded that, in the present study, H. pylori clarithromycin-resistant strains are more frequently found in children, in patients mostly born in Spain, and in individuals who were previously treated for H. pylori infection and that these individuals are more likely colonized with a less virulent H. pylori strain.

show abstract

Primary Clarithromycin Resistance to Helicobacter pylori and Therapy Failure in Children: The Experience in West Virginia

Cited by 16 publications

References 13 publications

Detection of Clarithromycin‐Resistant Helicobacter pylori by Stool PCR in Children: A Comprehensive Review of Literature

Detection of Clarithromycin‐Resistant Helicobacter pylori by Stool PCR in Children: A Comprehensive Review of Literature

Time Trends of Helicobacter pylori Resistance to Antibiotics in Children Living in Vienna, Austria

High Prevalence of Clarithromycin-Resistant Helicobacter pylori Strains and Risk Factors Associated with Resistance in Madrid, Spain

Contact Info

Product

Resources

About